Oxidative modification enhances lipoprotein(a)-induced overproduction of plasminogen activator inhibitor-1 in cultured vascular endothelial cells

Atherosclerosis

Volumn 128, Issue 1, 1997, Pages 1-10

  Ren, Song ^a   Man, Ricky Y K ^a,b   Angel, Aubie ^a   Shen, Garry X ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Endothelial cells; Lipoprotein(a); Oxidative modification; Plasminogen activator inhibitor 1

Indexed keywords

COPPER SULFATE; DACTINOMYCIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LIPOPROTEIN METABOLISM; NORTHERN BLOTTING; OXIDATION; PRIORITY JOURNAL; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

BLOTTING, NORTHERN; CELLS, CULTURED; COPPER SULFATE; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LIPOPROTEIN(A); OXIDATION-REDUCTION; PLASMINOGEN ACTIVATOR INHIBITOR 1; RNA, MESSENGER; THIOBARBITURIC ACID REACTIVE SUBSTANCES; UMBILICAL VEINS;

EID: 0031043615     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(96)05971-0     Document Type: Article

References (39)

1. Berg K. Lp(a) lipoprotein: an overview. Chem Phys Lipids 1994;67-68:9.
2. Austin MA, Hokanson JE. Epidemiology of triglyceride, small dense low density lipoprotein, and lipoprotein(a) as risk factor for coronary heart disease. Med Clin North Am 1994;78:99.
3. Hajjar KA, Gavish D, Breslow JL, Nachinann RL. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 1989;339:303.
4. Lawn RM, Wade DP, Hammer RE, Chilesa O, Verstyft JO, Rubin EM. Atherogenesis in transgenic mice expressing human lipoprotein(a). Nature 1992;360:670.
5. Eaton DL, Fless GM, Kohr WJ, McLean 3W, Xu Q-T. Miller CG, Lawn RM, Scanu AM. Partial amino acids sequence of apolipoprotein(a) shows that it is homologous to plasminogen. Proc Natl Acad Sci USA 1987;84:3224.
6. Gonzalez-Gronow M, Edelberg JM, Pizzo SV. Further characterization of the cellular plasminogen binding site: evidence that plasminogen 2 and lipoprotein(a) compete for the same site. Biochemistry 1989;960:91.
7. Edelberg JM, Gonzalez-Gronow M, Pizzo SV. Lipoprotein(a) inhibition of plasminogen activation by tissue-type plasminogen activator. Thromb Res 1990;57:155.
8. Edelberg JM, Gonzalez-Gronow M, Pizzo SV. Lipoprotein(a) inhibits streptokinase-mediated activation of human plasminogen. Biochemistry 1989;28:2370.
9. Naruszewicz M, Giroux LM, Davignon J. Oxidative modification of Lp(a) causes changes in the structure and biological properties of Lp(a). Chem Phys Lipids 1994;167:67-68
10. Hamsten A, Walldius O, Szaposi, Blomback M, De Faire U, Dahlen O, Landou C, Wiman B. Plasminogen activator inhibitor in plasma. Lancet 1987;2:3.
11. Cortellaro M, Cofrancesco E, Boschetti C, Mussoni L, Donati MB, Caralano M, Gabrielli L, Lombard B, Specchia O. Increased fibrin turnover and high PAI-1 activity as predictor of ischemic events in atherosclerotic patients. A case control study. The PLAT Group. Arterioscler Thromb 1993;13:1412.
12. Terres W, Krewitt M, Hamm CW. Effects of lipoprotein(a) in vitro lysis of whole blood thrombi from healthy volunteers. Thromb Res 1993;69:479.
13. Yamazaki M, Asakura H, Jokaji H, Saito M, Uotani C, Kumabashiri I, Morishita E, Aoshima K, Ikeda T, Matsuda T. Plasma levels of lipoprotein(a) are elevated in patients with the antiphospholipid antibody syndrome. Thromb Haemost 1994;71:424.
14. Levin EG, Marzek U, Anderson J, Harker LA. Thrombin stimulates tissue plasminogen activator release from cultured human endothelial cells. J Clin Invest 1984;74:1988.
15. Konkle BA, Ginsburg D. The addition of endothelial cell growth factor and heparin to human umbilical vein endothelial cell cultures decreases plasminogen activator inhibitor-1 expression. J Clin Invest 1988;82:579.
16. Van Hinsberg VW, Bertibna RM, van WUngaarden A, van Tilburg NH, Emeis JJ, Haverkate F. Activated protein C decrease plasminogen activator-inhibitor activity in endothelial cell-conditioned medium. Blood 1985;65:444.
17. Emeis JJ, Kooistra T. Interleukin 1 and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J Exp Med 1986;163:1260.
18. Stiko-Rahm A, Wiman B, Hamsten A, Nilsson J. Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis 1990;10:1067.
19. Tremoli E, Camera M, Maderna P, Sironi L, Prati L, Colli S, Piovella F, Bernini F, Corsini A, Mussoni L. Increased synthesis of plasminogen activator inhibitor-1 by cultured human endothelial cells exposed to native and modified LDLs: an LDL receptor-independent phenomenon. Arterioscler Thromb 1993;13:338.
20. Latron Y, Chautan M, Anfosso F, Alessi MC, Nalbone O, Lafont H, Juhan-Vague I. Stimulating effect of oxidized low density lipoprotein on plasminogen activator inhibitor-1 synthesis by endothelial cells. Arterioscler Thromb 1991;11:1821.
21. Chautan M, Latron Y, Anfosso F, Alessi MC, Lafont H, Juhan-Vague I, Nalbone O. Phospatidylinositol turnover during stimulation of plasminogen activator inhibitor-1 secretion induced by oxidized low density lipoproteins in human endothelial cells. J Lipid Res 1993;34:101.
22. Kugiyama K, Sakamoto T, Misumi I, Sugiyama S, Ohgushi M, Ogawa H, Horiguchi M, Yasue H. Transferable lipids in oxidized low-density lipoprotein stimulate plasminogen activator inhibitor-1 and inhibit tissue-type plasminogen activator release from endothelial cells. Circ Res 1993;73:335.
23. Etingin OR, Hajjar DP, Hajjar KA, Harpel PC, Nachman RL. Lipoprotein(a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. J Biol Chem 1991;266:2456.
24. Snyder ML, Polacek D, Scanu AM, Fless GM. Comparative binding and degradation of lipoprotein(a) and low density lipoprotein by human monocyte-derived macrophages. J Biol Chem 1992;267:339.
25. Shen GX, Mymin D, Dembinski T, Krahn A, Angel A. Polymorphism and peripheral levels of apolipoprotein(a) in polygenic hypercholesterolemia and combined hyperlipidemia. Clin Invest Med 1995;18:33.
26. George R, Barber DL, Schneider WJ. Characterization of the chicken oocyte receptor for low and very low density lipoproteins. J Biol Chem 1987;262:16838.
27. Liu SY, Choy S, Dembinski TC, Hatch GM, Mymin D, Shen GX, Angel A, Choy PC, Man RYK. Alteration of lysophosphatidylcholine content in low density lipoprotein after oxidative modification: relationship to endothelium dependent relaxation. Cardiovas Res 1994;28:1476.
28. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351.
29. Chirgwin JM, Pryzbyla AE, MacDonald RJ, Rutter WJ. Isolation of biological active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 1979;18:5294.
30. Cockell KA, Ren S, Sun J, Angel A, Shen GX. Effect of thrombin on release of plasminogen activator inhibitor-1 from cultured primate arterial smooth muscle cells. Thromb Res 1995;77:119.
31. Climielewska J, Wiman B: Determination of tissue activator and its 'fast' inhibitor in plasma. Clin Chem 1986;32:482.
32. Noda-Heiny H, Fujii S, Sobel BE. Induction of vascular smooth muscle cell expression of plasminogen activator inhibitor-1 by thrombin. Circ Res 1993;72:36.
33. Dichek D, Quertermous T. Thrombin regulation of mRNA levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in cultured human umbilical vein endothelial cells. Blood 1989;74:222.
34. Levin EG, Miles LA, Fless GM, Scanu AM, Baynham P, Curtiss LK, Plow EF. Lipoproteins inhibits the secretion of tissue plasminogen activator from human endothelial cells. Arterioscler Thromb 1994;14:438.
35. Henrikson T, Mahoney EM, Steinberg D. Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: Recognition by receptors for acetyl low density lipoproteins. Proc Nat Acad Sci USA 1981;78:6499.
36. Yia-Herttuala S, Palinski W, Rosenfeld M, Parthasarathy S, Carew TE, Bulter S, Witztum JL, Steinberg D. Evidence for the presence of oxidized modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 1989;84:1086.
37. Naruszewicz M, Selinger E, Davignon J. Oxidized modification of lipoprotein(a) and the effect of beta-carotene. Metabolism 1992;41:1215.
38. Schleef RR, Podor TJ, Dunne E, Mimuro J, Loskutoff DJ. The majority of type I plasminogen activator inhibitor associated with cultured human endothelial cells is located under the cells and is accessible to solution-phase tissue-type plasminogen activator. J Cell Biol 1990;110:155.
39. Vargas FF, Caviedes PF, Grant DS. Electrophysiological characteristics of cultured human umbilical vein endothelial cells. Microvasc Res 1994;47:153.